After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for TG Therapeutics Inc (TGTX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.06, or 0.59%, to $10.31. The TG Therapeutics Inc has recorded 58,987 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that TG Therapeutics to Participate in the 5th Annual Guggenheim Inflammation, Neurology & Immunology (INI) Conference.
TGTX belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $10.25 and fluctuated between $11.17 as its day high and $10.05 as its day low. The current market capitalization of TG Therapeutics Inc is $1.55B. A total of 7.4 million shares were traded on the day, compared to an average of 5.51M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, TGTX has seen 5 BUY and 1 SELL insider trades, representing the acquisition of 180,000 and the disposition of 20,000 shares. Over the last 12 months, there were 8 BUYs and 4 SELLs from insiders. Insiders purchased 1,259,000 shares during that period but sold 158,501.
In the most recent transaction, WEISS MICHAEL S bought 100,000 shares of TGTX for 10.13 per share on Aug 11. After the transaction, the CEO and President now owns 12,073,021 company shares. In a previous transaction on Jun 23, Lonial Sagar sold 34,854 shares at 23.37 per share. TGTX shares that Director owns now total 93,878.
Among the insiders who sold shares, Power Sean A disposed of 73,647 shares on Jun 02 at a per-share price of $26.70. This resulted in the Chief Financial Officer holding 654,836 shares of TGTX after the transaction. In another insider transaction, Echelard Yann bought 9,000 shares at $10.64 per share on Jan 06. Company shares held by the Director now total 201,848.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for TGTX in the last 3 months, the mean price target is $26.83 with high estimates of $41.00 and low estimates of $6.00. In terms of 52-week highs and lows, TGTX has a high of $35.67 and a low of $5.16.
As of this writing, TGTX has an earnings estimate of $0.12 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of $0.62 per share and a lower estimate of -$0.28. The company reported an EPS of -$0.28 in the last quarter, which was 24.30% higher than expectations of -$0.37.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. TGTX’s latest balance sheet shows that the firm has $350.30M in Cash & Short Term Investments as of fiscal 2021. There were $79.05M in debt and $65.38M in liabilities at the time. Its Book Value Per Share was $0.27, while its Total Shareholder’s Equity was $237.15M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TGTX is Buy with a score of 4.38.